You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Myelodysplastic Syndromes

Showing 26 - 50 of 3,174
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MDS, Myeloproliferative Tumor, Anemia Trial in Tampa (Luspatercept)

Recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • Tampa, Florida
    Moffitt Cancer Center
Feb 16, 2023

Low Risk MDS Trial (R906289 Monosodium (R289 Na))

Not yet recruiting
  • Low Risk Myelodysplastic Syndromes
  • R906289 Monosodium (R289 Na)
  • (no location specified)
Jul 22, 2022

Clonal Cytopenia of Undetermined Significance, MDS Trial in Saint Louis (Atorvastatin, Rosuvastatin)

Not yet recruiting
  • Clonal Cytopenia of Undetermined Significance
  • Myelodysplastic Syndromes
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 28, 2022

MDS, MDS Trial in Tampa, Boston, Houston (APR-548 + Azacitidine)

Terminated
  • MDS
  • Myelodysplastic Syndromes
  • APR-548 + Azacitidine
  • Tampa, Florida
  • +3 more
Jul 20, 2022

Interplay Between Immune and Metabolic Programs in

Recruiting
  • Myelodysplastic Syndromes
    • Toulouse, France
      IUCT-Oncopole University Hospital
    May 17, 2022

    Relapsed / Refractory MDS Trial (NCR300)

    Not yet recruiting
    • Relapsed / Refractory Myelodysplastic Syndromes
    • (no location specified)
    May 7, 2022

    Untreated Myelodysplastic Syndrome Trial in France (Onureg + Venetoclax)

    Not yet recruiting
    • Untreated Myelodysplastic Syndrome
    • Onureg + Venetoclax
    • Angers, France
    • +9 more
    Mar 13, 2023

    MDS, Chronic Myelomonocytic Leukemia Trial in Tianjin (BC3402, Azacitidine)

    Recruiting
    • Myelodysplastic Syndromes
    • Chronic Myelomonocytic Leukemia
    • Tianjin, Tianjin, China
      Institute of Hematology & Blood Diseases Hospital, Chinese Acade
    Jul 30, 2023

    Acute Myeloid Leukemia, MDS Trial in Rochester (Inpatient serious illness care program)

    Not yet recruiting
    • Acute Myeloid Leukemia
    • Myelodysplastic Syndromes
    • Inpatient serious illness care program
    • Rochester, New York
      University of Rochester
    Jun 21, 2022

    Based on Quantitative Pharmacology in Patients With Lenalidomide

    Recruiting
    • Multiple Myeloma
    • +2 more
      • Jinan, Shandong, China
        the First Affiliated Hospital of Shandong First Medical Universi
      Oct 3, 2023

      MDS Trial (AG-946, Placebo)

      Not yet recruiting
      • Myelodysplastic Syndromes
      • (no location specified)
      Aug 4, 2022

      Acute Myeloid Leukemia, MDS Trial in Hangzhou (Decitabine for Injection, VENCLYXTO)

      Not yet recruiting
      • Acute Myeloid Leukemia
      • Myelodysplastic Syndromes
      • Hangzhou, Zhejiang, China
        The First Affiliated Hospital, College of Medicine, Zhejiang Uni
      Sep 18, 2023

      Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R Trial in Canada, United States (Etavopivat)

      Recruiting
      • Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
      • Ocala, Florida
      • +3 more
      Jan 30, 2023

      Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia Trial in Houston

      Recruiting
      • Chronic Myelomonocytic Leukemia
      • +5 more
      • Canakinumab
      • Houston, Texas
        M D Anderson Cancer Center
      Dec 7, 2022

      MDS Trial (Roxadustat in combination with retinoic acid)

      Not yet recruiting
      • Myelodysplastic Syndromes
      • Roxadustat in combination with retinoic acid
      • (no location specified)
      Aug 26, 2023

      MDS Trial in Beijing (Roxadustat, Luspatercept)

      Not yet recruiting
      • Myelodysplastic Syndromes
      • Beijing, China
        Peking union medical college hospital
      Aug 17, 2023

      Recurrent/Refractory Acute Myeloid Leukemia, MDS Trial in ChengDu (TQB2618 injection azacitidine, AZA decitabine, DAC)

      Recruiting
      • Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
      • TQB2618 injection azacitidine, AZA decitabine, DAC
      • ChengDu, Sichuan, China
        West China Hospital of Sichuan University
      Jun 16, 2022

      Luspatercept in Korean Myelodysplastic Syndrome or ß-thalassemia

      Not yet recruiting
      • Myelodysplastic Syndrome
      • Beta Thalassemia
      • Seoul, Korea, Republic of
        Bristol-Myers Squibb YH
      Oct 3, 2023

      MDS, Acute Myeloid Leukemia Trial (Sabatolimab, Magrolimab, Azacitidine)

      Not yet recruiting
      • Myelodysplastic Syndromes
      • Acute Myeloid Leukemia
      • (no location specified)
      Sep 2, 2022

      MDS, Myeloproliferative Chronic Myelomonocytic Leukemia Trial in Houston (Cladribine, Cytarabine, Venetoclax)

      Recruiting
      • Myelodysplastic Syndromes
      • Myeloproliferative Chronic Myelomonocytic Leukemia
      • Houston, Texas
        M D Anderson Cancer Center
      Oct 31, 2022

      Iron Deficiency Anemia Trial in Australia, Israel, Romania (KER-047)

      Recruiting
      • Iron Deficiency Anemia
      • Adelaide, South Australia, Australia
      • +8 more
      Jun 23, 2023

      MDS, de Novo, MDS, Secondary, MDS, Previously Treated Trial in Boston (Venetoclax, Azacitidine, Cytarabine)

      Recruiting
      • Myelodysplastic Syndromes, de Novo
      • +10 more
      • Boston, Massachusetts
        Dana-Farber Cancer Institute
      Jan 23, 2023

      Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy

      Recruiting
      • Myelodysplastic Syndromes
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Jan 31, 2023

        MDS, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic Trial in Newcastle (Subcutaneous azacitidine, Oral

        Not yet recruiting
        • Myelodysplastic Syndromes
        • +3 more
        • Subcutaneous azacitidine
        • Oral decitabine/cedazuridine
        • Newcastle, New South Wales, Australia
          Calvary Mater Newcastle
        May 29, 2023

        AML, ALL, Lymphoid Malignancies Trial in Birmingham (Infusion of CD34 selected hematopoietic stem cells)

        Not yet recruiting
        • AML
        • +5 more
        • Infusion of CD34 selected hematopoietic stem cells
        • Birmingham, Alabama
          University of Alabama at Birmingham
        Sep 14, 2023